Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 33.12% | -191.98% | 163.61% | -2.80% | -19.44% |
| Total Depreciation and Amortization | -3.78% | 6.50% | -5.00% | -10.76% | -23.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 608.54% | 94.06% | -211.16% | 347.84% | 140.07% |
| Change in Net Operating Assets | -51.28% | -313.08% | 131.38% | -568.80% | -106.71% |
| Cash from Operations | 16.03% | -1,018.27% | 88.58% | -20.85% | -149.96% |
| Capital Expenditure | 96.58% | -485.26% | -- | 100.00% | -1,722.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 96.58% | -485.26% | -- | 100.00% | -1,722.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.94% | -55.06% | -- | -100.00% | 880.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 96.70% | -16,402.81% | -- | -- |
| Cash from Financing | -87.41% | -0.44% | 12,684.56% | -100.60% | 880.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.55% | -62.08% | 289.95% | -154.73% | -3.86% |